BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Skin cancer AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1
61 results:

  • 1. Evaluation of ABT-751, a novel anti-mitotic agent able to overcome multi-drug resistance, in melanoma cells.
    Mahgoub TM; Jordan EJ; Mahdi AF; Oettl V; Huefner S; O'Donovan N; Crown J; Collins DM
    Cancer Chemother Pharmacol; 2024 May; 93(5):427-437. PubMed ID: 38226983
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Acquired and intrinsic resistance to vemurafenib in BRAF
    Zhang P; Kuil LE; Buil LCM; Freriks S; Beijnen JH; van Tellingen O; de Gooijer MC
    FEBS Open Bio; 2024 Jan; 14(1):96-111. PubMed ID: 37953496
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Putative cancer Stem Cell Markers are Frequently Expressed by Melanoma Cells
    Speigl L; Janssen N; Weide B; Sinnberg T; Pawelec G; Shipp C
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):193. PubMed ID: 37796710
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. PGC1-α-driven mitochondrial biogenesis contributes to a cancer stem cell phenotype in melanoma.
    Fontana F; Macchi C; Anselmi M; Rizzuto AS; Ruscica M; Limonta P
    Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166897. PubMed ID: 37758066
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Neuropilin-2 Inhibits Drug Resistance and Progression of Melanoma Involving the MiR-331-3p Regulated Cascade.
    Xie Q; Zhang R; Liu D; Yang J; Hu Q; Shan C; Li X
    Curr Mol Pharmacol; 2023; 16(7):787-799. PubMed ID: 36545728
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer.
    Yokota H; Sato K; Sakamoto S; Okuda Y; Fukuda N; Asano M; Takeda M; Nakayama K; Miura M
    Invest New Drugs; 2022 Dec; 40(6):1254-1262. PubMed ID: 36149549
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. p38 MAPK-dependent phosphorylation of transcription factor SOX2 promotes an adaptive response to BRAF inhibitors in melanoma cells.
    Pietrobono S; De Paolo R; Mangiameli D; Marranci A; Battisti I; Franchin C; Arrigoni G; Melisi D; Poliseno L; Stecca B
    J Biol Chem; 2022 Sep; 298(9):102353. PubMed ID: 35944584
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. CDK7 and MITF repress a transcription program involved in survival and drug tolerance in melanoma.
    Berico P; Cigrang M; Davidson G; Braun C; Sandoz J; Legras S; Vokshi BH; Slovic N; Peyresaubes F; Gene Robles CM; Egly JM; Compe E; Davidson I; Coin F
    EMBO Rep; 2021 Sep; 22(9):e51683. PubMed ID: 34296805
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Desensitization of metastatic melanoma cells to therapeutic treatment through repeated exposure to dacarbazine.
    Biteghe FAN; Padayachee E; Davids LM; Chalomie NET; Ndong JC; Barth S
    J Photochem Photobiol B; 2020 Oct; 211():111982. PubMed ID: 32866820
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Cannabidiol Effects on Phospholipid Metabolism in Keratinocytes from Patients with Psoriasis Vulgaris.
    Jarocka-Karpowicz I; Biernacki M; Wroński A; Gęgotek A; Skrzydlewska E
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32121131
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.
    Goey AK; With M; Agema BC; Hoop EO; Singh RK; van der Veldt AA; Mathijssen RH; van Schaik RH; Bins S
    Pharmacogenomics; 2019 Dec; 20(18):1283-1290. PubMed ID: 31829834
    [No Abstract]    [Full Text] [Related]  

  • 12. Metabolome Analysis Reveals Dermal Histamine Accumulation in Murine Dermatitis Provoked by Genetic Deletion of P-Glycoprotein and Breast cancer Resistance Protein.
    Hashimoto N; Nakamichi N; Nanmo H; Kimura KI; Masuo Y; Sakai Y; Schinkel AH; Sato S; Soga T; Kato Y
    Pharm Res; 2019 Sep; 36(11):158. PubMed ID: 31512001
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors.
    Reddick SJ; Campagne O; Huang J; Onar-Thomas A; Broniscer A; Gajjar A; Stewart CF
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):829-838. PubMed ID: 31392390
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.
    Hayashi H; Iihara H; Hirose C; Fukuda Y; Kitahora M; Kaito D; Yanase K; Endo J; Ohno Y; Suzuki A; Sugiyama T
    Lung Cancer; 2019 Aug; 134():1-6. PubMed ID: 31319966
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice.
    Al-Shammari AH; Masuo Y; Fujita KI; Yoshikawa Y; Nakamichi N; Kubota Y; Sasaki Y; Kato Y
    J Pharm Sci; 2019 Jun; 108(6):2173-2179. PubMed ID: 30685396
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases.
    Gampa G; Kim M; Mohammad AS; Parrish KE; Mladek AC; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2019 Mar; 368(3):446-461. PubMed ID: 30622172
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A Proof-of-Concept Study to Inhibit abcg2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier.
    Bauer M; Karch R; Wulkersdorfer B; Philippe C; Nics L; Klebermass EM; Weber M; Poschner S; Haslacher H; Jäger W; Tournier N; Wadsak W; Hacker M; Zeitlinger M; Langer O
    J Nucl Med; 2019 Apr; 60(4):486-491. PubMed ID: 30237210
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. In silico analysis of nsSNPs in ABCB1 gene affecting breast cancer associated protein P-glycoprotein (P-gp).
    Chakraborty R; Gupta H; Rahman R; Hasija Y
    Comput Biol Chem; 2018 Dec; 77():430-441. PubMed ID: 30181081
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Cytotoxicity of 18 Cameroonian medicinal plants against drug sensitive and multi-factorial drug resistant cancer cells.
    Mbaveng AT; Manekeng HT; Nguenang GS; Dzotam JK; Kuete V; Efferth T
    J Ethnopharmacol; 2018 Aug; 222():21-33. PubMed ID: 29709646
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol.
    Marzagalli M; Moretti RM; Messi E; Marelli MM; Fontana F; Anastasia A; Bani MR; Beretta G; Limonta P
    Sci Rep; 2018 Jan; 8(1):587. PubMed ID: 29330434
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.